CLARINEX (desloratadine) by Merck & Co. is 1 -receptor histamine antagonist activity. First approved in 2004.
Drug data last refreshed 2h ago · AI intelligence enriched 3w ago
CLARINEX (desloratadine) is an oral H1-receptor histamine antagonist approved for allergic rhinitis, indicated to relieve symptoms including sneezing, itching, watery eyes, and nasal congestion. It works by blocking histamine at the H1 receptor on mast cells without significant central nervous system penetration, providing targeted peripheral antihistamine activity.
Declining lifecycle stage with minimal Part D utilization signals contraction in brand team size and commercial investment.
1 -receptor histamine antagonist activity. Receptor binding data indicate that at a concentration of 2 to 3 ng/mL (7 nanomolar), desloratadine shows significant interaction with the human histamine H 1 receptor. Desloratadine inhibited histamine release from human mast cells in vitro . Results of a…
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Desloratadine,Phenylephrine Hcl,Ibuprofen Compared to Placebo in Treatment of Symptoms Associated With Common Cold/Flu
Comparison of Desloratadine Associated With Prednisolone Oral Solution Versus Dexchlorpheniramine Associated With Betamethasone for Cutaneous Rash Treatment
Comparison of Desloratadine Associated With Prednisolone Oral Solution Versus Dexchlorpheniramine Associated With Betamethasone for Persistent Allergic Rhinitis Treatment
Comparison of Desloratadine Associated With Prednisolone (Tablet)Versus Dexchlorpheniramine Associated With Betamethasone (Tablet) for Adult Persistent Allergic Rhinitis Treatment
Bioequivalence Study of Desloratadine and Pseudoephedrine Sulfate Extended-release Tablets Under Fasting Conditions
Worked on CLARINEX at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moCLARINEX represents a post-launch, mature asset with minimal linked job openings and declining commercial momentum, making it a lower-priority career destination for growth-oriented professionals. Roles focus on defensive market management and generic containment rather than expansion or innovation.